- Home
- Publications
- Publication Search
- Publication Details
Title
Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
Authors
Keywords
-
Journal
MOLECULES
Volume 24, Issue 8, Pages 1559
Publisher
MDPI AG
Online
2019-04-22
DOI
10.3390/molecules24081559
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Repair of DNA double-strand breaks by mammalian alternative end-joining pathways
- (2018) Annahita Sallmyr et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Base-promoted nucleophilic fluoroarenes substitution of C F bonds
- (2018) Ji Su et al. TETRAHEDRON
- Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects
- (2018) Cho Rong Hong et al. BIOCHEMICAL PHARMACOLOGY
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
- (2016) Roger M. Phillips CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PARP inhibitor combination therapy
- (2016) Amy Dréan et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer
- (2016) Rachel Nirsimloo et al. Expert Review of Anticancer Therapy
- Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
- (2016) Ann-Gerd Thorsell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs
- (2016) Liam J O'Connor et al. Nature Protocols
- The discovery of allyltyrosine based tripeptides as selective inhibitors of the HIV-1 integrase strand-transfer reaction
- (2016) Neal Dalton et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Total synthesis of penipanoid C, 2-(4-hydroxybenzyl)quinazolin-4(3H)-one and NU1025
- (2016) Suman Kr Ghosh et al. TETRAHEDRON LETTERS
- Pathophysiological Basis for the Formation of the Tumor Microenvironment
- (2016) Michael R. Horsman et al. Frontiers in Oncology
- Design and synthesis of new potassium channel activators derived from the ring opening of diazoxide: Study of their vasodilatory effect, stimulation of elastin synthesis and inhibitory effect on insulin release
- (2015) Nafila Bouider et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- A comparative synthesis of 6-benzyl-2,3-dihydroimidazo[2,1-a]phthalazine and 2H-7-benzyl-3,4-dihydropyrimido[2,1-a]phthalazine
- (2015) Javier Munín et al. TETRAHEDRON LETTERS
- Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors
- (2014) Ruth Plummer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
- (2013) Nicola J. Curtin et al. MOLECULAR ASPECTS OF MEDICINE
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
- (2013) Silvana B. De Lorenzo et al. Frontiers in Oncology
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- PARPs and the DNA damage response
- (2012) F. G. Sousa et al. CARCINOGENESIS
- A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
- (2012) A. Rajan et al. CLINICAL CANCER RESEARCH
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
- (2011) Jens Samol et al. INVESTIGATIONAL NEW DRUGS
- Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
- (2011) F. Meng et al. MOLECULAR CANCER THERAPEUTICS
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
- (2010) Dana V. Ferraris JOURNAL OF MEDICINAL CHEMISTRY
- The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
- (2010) Raga Krishnakumar et al. MOLECULAR CELL
- Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
- (2010) C. E. Strom et al. NUCLEIC ACIDS RESEARCH
- Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets
- (2010) Anthony J. Chalmers et al. SEMINARS IN RADIATION ONCOLOGY
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
- (2008) R. Plummer et al. CLINICAL CANCER RESEARCH
- Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs
- (2008) Jian-Xin Duan et al. JOURNAL OF MEDICINAL CHEMISTRY
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search